Gene
SUZ12
SUZ12 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (3), Actionable biomarkers (2), Trial mentions (1), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SUZ12. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
SUZ12 has 1 trial mention across 1 year. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 3 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 3 of 13,598 | 0.02% |
| 2021 | 1 of 8,692 | 0.01% | 7 of 15,045 | 0.05% |
| 2020 | 0 of 7,640 | 0.00% | 8 of 14,459 | 0.06% |
| 2019 | 0 of 7,300 | 0.00% | 4 of 12,159 | 0.03% |
| 2018 | 0 of 6,927 | 0.00% | 3 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
Assay-provider ledger (3)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Wuhan Iwill Biological Technology Co., Ltd. | Reagent supplier | Clinical validation | 1 | August 17, 2018 |
| Agilent | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | February 20, 2015 |
| Illumina | Unclassified | No clinical or analytical validation recorded for this pair | 1 | February 20, 2015 |
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SUZ12 oncogenic mutation | Bet Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
| SUZ12 deletion | Bet Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (1)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04872543 | Trial eligibility (AACT) |
Target-disease associations (354)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-M syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Acute Leukemia | cancer or benign tumor | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | GWAS credible sets |
| Anal Squamous Cell Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 354 associations.
Vendor sourcing (17)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Canonical splice site: predicted to alter splicing and result in a loss or disruption of normal protein function through protein truncation. Multiple pathoge... | View ClinVar record SCV002058912.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The alteration results in a premature stop codon: _x000D_ _x000D_ The c.361C>T (p.R121*) alteration, located in coding exon 3 of the SUZ12 gene, results from... | View ClinVar record SCV001444925.4 |
| Centre Hospitalier Universitaire de Nantes | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001334385.1 |
| DASA (Brazil) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | NM_015355.4(SUZ12):c.1023+1G>C introduces a premature termination codon predicted to result in loss of normal protein function. Loss-of-function is an establ... | View ClinVar record SCV007599478.1 |
| GeneDx Holdings Corp. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (Lek et al., 201... | View ClinVar record SCV000914205.3 |
Showing 5 of 17 sourcing records.
Trial-cited literature (66)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL. | Blood | 2024 | 11 |
| Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | Cancer discovery | 2023 | 83 |
| Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes. | Scientific reports | 2023 | 16 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| The genomic landscape of pediatric acute lymphoblastic leukemia. | Nature genetics | 2022 | 335 |
Showing 5 of 66 papers.
Protein variant mentions (1)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.Q599H | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (11)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Disease | associate |
Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL. | 2024 |
| Esophageal Squamous Cell Carcinoma | Disease | associate |
Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. | 2020 |
| Neoplasms | Disease | associate |
Genetics of human malignant peripheral nerve sheath tumors. | 2020 |
| Infratentorial Neoplasms | Disease | associate |
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. | 2018 |
| Neurofibrosarcoma | Disease | associate |
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. | 2017 |
Showing 5 of 11 relation assertions.
Organizations publishing (139)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 13 | 2008 to 2023 |
| Novant Health | Hospital | 8 | 2012 to 2022 |
| University of Alabama System | Academic | 5 | 2017 to 2023 |
| Utah System of Higher Education | Academic | 5 | 2017 to 2023 |
| Mass General Brigham | Hospital | 4 | 2014 to 2023 |
Showing 5 of 139 organizations.
Where SUZ12 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- reproductive system or breast disease
318 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.